NCT04196816

Surgery for Pancreatic Cancer With Oligo-Metastasis

Surgery/Destruction for Stage IV Pancreatic Cancer With Oligo-Metastatic Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: University Hospital, Montpellier · Academic / Other
• Sex: All
• Age: 18 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019). However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients. The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Conditions

• Pancreatic Cancer
• Pancreatic Surgery

Timeline

• Start date: 2020-01-01
• Primary completion: 2020-03-01
• Completion: 2020-12-01
• First posted: 2019-12-12
• Last updated: 2020-12-29

Locations

1 site across 1 country: France